key: cord-0748145-8efiqd2t authors: Al‐Riyami, Arwa Z.; Burnouf, Thierry; Wood, Erica M.; Devine, Dana V.; Oreh, Adaeze; Apelseth, Torunn Oveland; Goel, Ruchika; Bloch, Evan M.; van Den Berg, Karin; Getshen, Mahrukh; Louw, Vernon; Ang, Ai Leen; Lee, Cheuk Kwong; Rahimi‐Levene, Naomi; Stramer, Susan L.; Vassallo, Ralph; Schulze, Torsten J.; Patidar, Gopal Kumar; Pandey, Hem Chandra; Dubey, Rounak; Badawi, Maha; Hindawi, Salwa; Meshi, Abdullah; Matsushita, Tadashi; Sorrentino, Enrico; Grubovic Rastvorceva, Rada M.; Bazin, Renée; Vermeulen, Marion; Nahirniak, Susan; Tsang, Hamilton C.; Vrielink, Hans; Triyono, Teguh; Addas‐Carvalho, Marcelo; Hećimović, Ana; Torres, Oscar W.; Mutindu, Samclide M.; Bengtsson, Jesper; Dominguez, Diego; Sayedahmed, Ahmed; Hanisa Musa, Rozi; Gautam, Bipul; Herczenik, Eszter; So‐Osman, Cynthia title: International Society of Blood Transfusion survey of experiences of blood banks and transfusion services during the COVID‐19 pandemic date: 2022-03-08 journal: Vox Sang DOI: 10.1111/vox.13256 sha: b5839b86251abb020537ecd94f1d7838cda14920 doc_id: 748145 cord_uid: 8efiqd2t BACKGROUND AND OBJECTIVES: The coronavirus disease 2019 (COVID‐19) pandemic has impacted blood systems worldwide. Challenges included maintaining blood supplies and initiating the collection and use of COVID‐19 convalescent plasma (CCP). Sharing information on the challenges can help improve blood collection and utilization. MATERIALS AND METHODS: A survey questionnaire was distributed to International Society of Blood Transfusion members in 95 countries. We recorded respondents' demographic information, impacts on the blood supply, CCP collection and use, transfusion demands and operational challenges. RESULTS: Eighty‐two responses from 42 countries, including 24 low‐ and middle‐income countries, were analysed. Participants worked in national (26.8%) and regional (26.8%) blood establishments and hospital‐based (42.7%) institutions. CCP collection and transfusion were reported by 63% and 36.6% of respondents, respectively. Decreases in blood donations occurred in 70.6% of collecting facilities. Despite safety measures and recruitment strategies, donor fear and refusal of institutions to host blood drives were major contributing factors. Almost half of respondents working at transfusion medicine services were from large hospitals with over 10,000 red cell transfusions per year, and 76.8% of those hospitals experienced blood shortages. Practices varied in accepting donors for blood or CCP donations after a history of COVID‐19 infection, CCP transfusion, or vaccination. Operational challenges included loss of staff, increased workloads and delays in reagent supplies. Almost half of the institutions modified their disaster plans during the pandemic. CONCLUSION: The challenges faced by blood systems during the COVID‐19 pandemic highlight the need for guidance, harmonization, and strengthening of the preparedness and the capacity of blood systems against future infectious threats. vaccination. Operational challenges included loss of staff, increased workloads and delays in reagent supplies. Almost half of the institutions modified their disaster plans during the pandemic. Conclusion: The challenges faced by blood systems during the COVID-19 pandemic highlight the need for guidance, harmonization, and strengthening of the preparedness and the capacity of blood systems against future infectious threats. The coronavirus disease 2019 (COVID-19) pandemic has created challenges for many blood establishments (BEs) and transfusion medicine services (TMS) worldwide. African [1] , Asian [2] , Eastern Mediterranean [3] and some Western countries [4] [5] [6] reported blood supply challenges. They faced decreased rates of donations [1, 3] , public fear of infection when donating blood [7] and decreased numbers of, or outright cancellations of, blood drives [3] due to lockdown measures. In addition, unpredictable clinical demands for blood, linked to cancellations of elective surgeries and non-urgent interventions, were described, while blood demand for emergency situations and patients on chronic transfusion support remained relatively unchanged [3, 6] . Some centres reported lower blood supply in the early stages of the pandemic, compensated by decreased blood demand for elective surgeries and other medical procedures [8] . Many institutions collected COVID-19 convalescent plasma (CCP) and/or used it for passive immunotherapy on a compassionate basis or for clinical trials. Guidelines on the collection and use of CCP in high-income and low-and middle-income countries (LMICs) have been published [9] [10] [11] [12] [13] . During the period covered by the survey, the World Health Organization (WHO) developed interim guidances, which underwent updates throughout the pandemic, for maintaining a safe and adequate blood supply and applying COVID-19-related donor deferral criteria, temporary deferral after vaccination and CCP usage [14, 15] . Early in the pandemic, the International Society of Blood Transfusion (ISBT) established a multidisciplinary working group, comprised of international transfusion experts, to review the impacts of COVID-19 on blood systems and existing practices on CCP collection and use from donor, product and patient perspectives [11, [16] [17] [18] . This survey aims to assess the impact of COVID-19 pandemic on BEs and TMS around the world to summarize the experiences and provide guidance to prepare for future pandemics. A web-based survey was designed using Survey Monkey and piloted for content validity and avoidance of ambiguity by the working group. The survey, written in English, was distributed by the ISBT central office to 1481 ISBT members from 95 countries spanning all WHO regions. Respondents provided consent through completing the survey. Data were collected between 25 May and 9 July 2021. The survey contained 77 questions covering demographics (n = 13), and questions tailored to BEs (n = 33) and TMS (n = 31) and others addressing blood supply challenges (n = 10) and demand (n = 11), and CCP collection (n = 23) and transfusions (n = 15). All respondents were invited to complete five questions on the operational challenges faced and to list recommendations for future pandemics. Descriptive statistics were performed, and the reported variables are expressed in numbers and percentages. Ninety-three ISBT members participated. In total, 82 responses from 42 countries across all WHO regions, including 24 LMICs [19] , were included in the analysis after excluding participants with <75% completion of the survey (Figure 1 ; Table S1 ). At the time of completion of this survey, most respondents indicated that their countries were either in the second wave of COVID-19 with a decreasing number of cases or in the third wave with either decreasing or increasing number of cases. Almost two-thirds of respondents from BEs and hospital-based blood services indicated a decrease in donations during the pandemic, while 23.5% reported fluctuations (Table S2 ). Blood donation drives were either cancelled or decreased in two-thirds of institutions, primarily due to increased COVID-19 cases and lockdowns. Several institutions reported blood donors' fear of visiting hospital-based blood banks. Other stated reasons were donor deferrals due to infections or quarantine requirements. Some respondents described declines during the lockdown period in the first wave, while in a few countries, the number of donors decreased at the start of the pandemic but improved over the following months. One respondent reported decreased donations at the start of the pandemic due to increasing imported cases with a lockdown, followed by a temporary recovery before a drop due to surging numbers of COVID-19 cases. A respondent from a blood collector in the United States described a sharp decline in blood donations when COVID-19 was declared a national emergency and stay-at-home orders were mandated in multiple states. Free donor testing for antibodies against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) was initiated, and donations steadily increased thereafter. Other respondents shared similar experiences, unveiling a decline in blood donations in the first and third waves of the pandemic, with decreased demand for elective surgeries and transplants, followed by an increase over the usual demand thereafter. In contrast, in Italy, donations increased in the early stages of the pandemic as a result of calls for blood donors. At the time of undertaking this survey, most institutions were applying a 14-(50.7%) or 28-day (38.8%) deferral period for donors with a history of COVID-19 infection after full recovery/resolution of symptoms (Table S2 ). In one Nigerian institution, testing for COVID-19 was needed before a blood donation. Policies with regard to donor deferral after a CCP transfusion varied. Over one-quarter of respondents (27.7%) indicated a 12-month temporary deferral, and 7.7% respondents reported permanent deferral (from the Netherlands, Malaysia, Congo, Kenya and one center in Saudi Arabia), while 13.8% were awaiting a policy decision. In Germany, a 4-month deferral period was applied. (Table S2) In the United States, individuals who received a live-attenuated viral vaccine had to refrain from donating blood for 14 days, but no such vaccines were authorized in that country. In Singapore, individuals receiving mRNA or inactivated vaccines were deferred by the national BE for 3 days post vaccination if free from side effects, for 1 week after resolution of localized pain at the injection site and for 4 weeks after resolution of a fever, generalized muscle aches, rashes, or lymph node swelling. The deferral period for vector-based or liveattenuated vaccines was 28 days. Safety measures were implemented to protect donors and staff in BEs and hospital-based blood services (Table S2) The most common challenges were donor fear of contracting COVID-19 at blood donation facilities, refusal of partner institutions to host blood drives and lockdowns (Table S2) [20] . Another operation allocated funds to retain workers and provided supplies including thermometers, personal protective equipment (PPE) and hand-held equipment at blood drives. Fifty-two institutions collected CCP during the pandemic (Table S3) Three-quarters of the 56 TMS experienced blood shortages during the COVID-19 pandemic, and in 35 (62.5%), the shortage correlated with the number of cases reported in their countries (Table S4) Thirty TMS transfused CCP to patients with SARS-CoV-2 infection, including five that transfused CCP into paediatric patients (Table S5 ). More than half of institutions transfused CCP as part of national F I G U R E 2 Operational recommendations for blood establishments and transfusion services to prepare for future viral threats/pandemics. CCP, COVID-19 convalescent plasma; PBM, patient blood management; PPE, personal protective equipment; NGO, non-governmental organization programmes (60%) and for both clinical trials and compassionate/ emergency use. Most institutions enrolled in clinical trials used CCP therapeutically for hospitalized patients. Only three institutions were enrolled in clinical trials assessing CCP use in a pre-hospital setting, and only one as a prophylactic measure for high-risk exposure. The vast majority of institutions utilizing CCP on a compassionate basis used a specific consent form for treated patients. More than half of the respondents indicated having sufficient CCP supply. The protocol for unit selection-if more than one dose of CCP was given-ranged from random selection to selecting units from the same donor (Table S5) . ABO-matched CCP was used by 56.7% of the respondents. The ISBT haemovigilance definition was used by 46.7% of institutions when reporting adverse reactions to transfused CCP [22] . Most institutions reported to the blood bank, national haemovigilance committee and/or a blood transfusion/safety committee. The commonest operational challenges faced during the pandemic were staff losses due to sickness or quarantine and increased workloads (Table S6 ). More than one-quarter of respondents reported staff deployment to other services such as to support a virology laboratory. One-third of respondents reported a lack of PPE. Other challenges included delays in reagent supplies and instrument maintenance, and the need for team segregation for business continuity planning, resulting in longer working hours and higher workloads in blood processing and testing laboratories. A respondent from one LMIC described a lack of support for blood systems in the country. Challenges upon initiating a CCP collection and transfusion programme included cost/funding, setting up clinical trials, and obtaining institutional review board approvals. One respondent from Africa described challenges with the lack of sufficiently qualified physicians to initiate clinical trials and slow initial patient enrollment. Another respondent described donor recruitment as the main challenge, as donors were unwilling to come to the hospital to donate CCP or had transportation difficulties due to lockdowns. Two respondents indicated that collecting CCP on a voluntary, non-remunerated basis without proof of its benefits for hospitalized patients was extremely difficult. Challenges with the demand exceeding supply at certain stages of the pandemic were described by respondents from India and Portugal. Other challenges included donor recruitment and eligibility determination, managing human and testing resources, apheresis equipment and required logistics. Respondents shared the lessons learned and recommendations to help in preventing/managing blood shortages, meeting transfusion demands during a pandemic, establishing a CCP programme and overcoming operational challenges (Table S7 ; Figure 2 ). To the best of our knowledge, this is the largest survey conducted to assess the impact of the COVID-19 pandemic on BEs and TMS worldwide. This survey highlights some specific challenges faced during different waves of the pandemic and the mitigation steps undertaken. National measures to contend with the pandemic had negative impacts on the blood supply in most BEs, with the demand fluctuating in half of the TMS. Challenges included public fear, transport restrictions and staff shortages. These specifically threatened transfusion support to certain patient populations in some institutions, in line with previous reports [3, [23] [24] [25] . Although cancellations of surgeries were reported to decrease blood demand in the early stages of the pandemic [8, 26] , most of the participants reported blood shortages. This could be explained by the proportion of participants in our survey from LMICs. The fragility of blood supply systems in LMICs likely makes it particularly challenging for blood banks in those countries to meet ongoing demands. In the early stages of the pandemic, the WHO recommended that centres be prepared to move quickly in response to changes in managing demands for blood and blood products while mitigating potential risks to staff and donors from exposure to SARS-CoV-2 [15] . With universal impacts on the blood supply and donation rates, there is a need for a global message to the public and national authorities on the continuing need for blood donors. We report variation in certain practices, such as donor deferral post-recovery from COVID-19 or for recipients of CCP transfusions, and deferral after receiving COVID-19 vaccines for blood and CCP donations. While there was guidance from different organizations such as the WHO [14] , ISBT [9, 11] and Association for the Advancement of Blood & Biotherapies [12] , there was variability in practice, which may be ascribed to slightly diverging recommendations in those guidelines over time, local policies and regulations, resources, facilities and expertise. This highlights the need for harmonization of international guidelines and updating them as scientifically based knowledge and circumstances (such as vaccinations) evolve throughout the pandemic. A harmonized reporting scheme for CCP reactions is also required. This survey also highlights the wide range of operational challenges encountered during the pandemic. The lack of PPEs in onethird of institutions reflects that experienced in other sectors of healthcare systems worldwide, especially in the early stages of the pandemic [27, 28] . A lack of previous experience with pandemics resulted in one-half of the institutions changing their contingency/ disaster plans, which illustrates the need that essential plans be developed for pandemic preparedness, preferably in line with national policy responses. One limitation of this cross-sectional survey is that it captured data only at a single moment in time. Hence, the survey results do not reflect the trend or the magnitude of the blood shortages and challenges observed beyond the period assessed. This limitation is particularly relevant considering the variable degree of virus spread between different countries worldwide. In addition, relying on voluntary participants may have introduced a selection bias. Furthermore, a nonresponse bias could arise, as the set of people willing to participate may differ from those who did not respond. Finally, the survey was provided only in English, which may have hindered non-English-speaking respondents. However, to the best of our knowledge, this is the most extensive assessment of the impact of the COVID-19 pandemic on BEs and TMS worldwide. The participation from all WHO regions provides a broad comparative snapshot of this impact. In conclusion, the COVID-19 pandemic imposed challenges on BEs and TMS worldwide. The information gathered through this survey and recommendations can be used to guide policymakers and governmental and non-governmental organizations to strengthen the capacities of national blood transfusion systems, enhance risk mitigation and develop preparedness plans for future pandemics. Impact of the COVID-19 pandemic on blood supply and demand in the WHO African Region COVID-19 pandemic-blood supply challenges and approaches in AATM member countries The impact of COVID-19 pandemic on blood supplies and transfusion services in Eastern Mediterranean Region The impact of the SARS-CoV-2 outbreak on the safety and availability of blood transfusions in Italy Prepare to adapt: blood supply and transfusion support during the first 2weeks of the 2019 Novel Coronavirus (COVID-19) pandemic affecting Washington State Blood use and transfusion needs at a large health care system in Washington state during the SARS-CoV-2 pandemic Impact of COVID-19 on blood centres in Zhejiang province China Effects of the COVID-19 pandemic on supply and use of blood for transfusion Guidance for the procurement of COVID-19 convalescent plasma: differences between high-and low-middle-income countries Points to consider in the preparation and transfusion of COVID-19 convalescent plasma Clinical use of convalescent plasma in the covid-19 pandemic: a transfusion-focussed gap analysis with recommendations for future research priorities COVID-19 convalescent plasma: interim recommendations from the AABB Use of COVID-19 convalescent plasma in low-and middle-income countries: a call for ethical principles and the assurance of quality and safety Maintaining a safe and adequate blood supply and collecting convalescent plasma in the context of the COVID-19 pandemic Interim guidance. Geneva: World Health Organization 2021 COVID-19) pandemic and on the collection of COVID-19 convalescent plasma. Geneva: World Health Organization International forum on the collection and use of COVID-19 convalescent plasma: responses. Vox Sang International forum on the collection and use of COVID-19 convalescent plasma: protocols, challenges and lessons learned: summary. Vox Sang Lessons learned in the collection of convalescent plasma during the COVID-19 pandemic World Bank Country and Leading Groups Virtual blood drive Investigational COVID-19 convalescent plasma-Guidance for Industry. Food and Drug Administration Proposed Standard Definitions for surveillance of non infectious adverse transfusion reactions The forgotten people with thalassemia in the time of COVID-19: South Asian perspective Challenging times for children with transfusiondependent thalassemia amid the COVID-19 pandemic Preliminary data on COVID-19 in patients with hemoglobinopathies: a multicentre ICET-a study Vox Sanguinis international forum on hospital transfusion services' response to COVID-19 Shortage of personal protective equipment endangering healthcare workers worldwide Global shortage of personal protective equipment SUPPORTING INFORMATION Additional supporting information may be found in the online version of the article at the publisher's website. How to cite this article International Society of Blood Transfusion survey of experiences of blood banks and transfusion services during the COVID-19 pandemic COVID-19 INTERNATIONAL BLOOD SURVEY We acknowledge the ISBT Central Office staff for the support in designing and distributing the survey, and the experts who participated in this survey (Appendix S1). The authors declare no conflicts of interest.